ArticleFrontiers in immunology2024
Preparation and application of a
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multiepitope fusion protein-based ELISA for enhanced brucellosis serodiagnosis.PLoS neglected tropical diseases · 2025Article
- Development and evaluation of multiepitope fusion proteins for serological diagnosis of animal brucellosis.Microbiology spectrum · 2025Article
- Delayed diagnosis of pediatric brucellosis: a case study and literature review.Annals of medicine and surgery (2012) · 2025Article
- Preparation of a Brucella multiepitope fusion protein based on bioinformatics and its application in serological diagnosis of human brucellosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brucellosis is a widespread zoonotic disease that poses a considerable challenge to global public health. Existing diagnostic methods for this condition, such as serological assays and bacterial culture, encounter difficulties due to their limited specificity and high operational complexity. Therefore, there is an urgent need for the development of enhanced diagnostic approaches for brucellosis. Methods: Tandem mass tag (TMT) proteomic analysis was conducted on the wild-type strain Results: Proteomic analysis revealed the presence of 152 proteins with high expression levels in the wild-type strains. A multiepitope fusion protein, comprising a total of 32 predicted B-cell linear epitopes, was successfully prepared. The results from the iELISA indicated that the multiepitope fusion protein exhibited exceptional diagnostic performance, evidenced by an area under the receiver operating characteristic curve (AUC) of 0.9576, a sensitivity of 0.9300, and a specificity of 0.8542. In comparison to the commonly utilized LPS antigen, the fusion protein demonstrated a reduced level of cross-reactivity. Conclusions: A novel multiepitope fusion protein has been successfully developed utilizing bioinformatics and TMT proteomics technology. This fusion protein demonstrates significant potential as a diagnostic antigen for brucellosis, exhibiting high sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.